{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "earningsTimestamp": 1682679614, "earningsTimestampStart": 1687350600, "earningsTimestampEnd": 1687782600, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -46.58, "epsForward": 0.03, "sharesOutstanding": 2949270, "bookValue": -28.84, "fiftyDayAverage": 4.142, "fiftyDayAverageChange": -1.8520002, "fiftyDayAverageChangePercent": -0.447127, "twoHundredDayAverage": 15.8377, "twoHundredDayAverageChange": -13.5477, "twoHundredDayAverageChangePercent": -0.8554083, "marketCap": 6959378, "forwardPE": 76.333336, "priceToBook": -0.0794036, "currency": "USD", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "regularMarketChangePercent": -0.4347822, "regularMarketPrice": 2.29, "firstTradeDateMilliseconds": 1357569000000, "priceHint": 4, "preMarketChange": -0.00999999, "preMarketTime": 1684228951, "exchange": "NGM", "shortName": "Redhill Biopharma Ltd.", "longName": "RedHill Biopharma Ltd.", "messageBoardId": "finmb_104926324", "preMarketChangePercent": -0.4347822, "regularMarketChange": -0.00999999, "preMarketPrice": 2.29, "regularMarketTime": 1684180794, "regularMarketDayHigh": 2.35, "regularMarketDayRange": "2.1914 - 2.35", "regularMarketDayLow": 2.1914, "regularMarketVolume": 38679, "regularMarketPreviousClose": 2.3, "bid": 0.0, "ask": 0.0, "bidSize": 12, "askSize": 22, "fullExchangeName": "NasdaqGM", "financialCurrency": "USD", "regularMarketOpen": 2.3, "averageDailyVolume3Month": 100982, "averageDailyVolume10Day": 91680, "fiftyTwoWeekLowChange": 0.24000001, "fiftyTwoWeekLowChangePercent": 0.11707318, "fiftyTwoWeekRange": "2.05 - 49.2", "fiftyTwoWeekHighChange": -46.91, "fiftyTwoWeekHighChangePercent": -0.95345527, "fiftyTwoWeekLow": 2.05, "fiftyTwoWeekHigh": 49.2, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "displayName": "RedHill Biopharma", "symbol": "RDHL"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "21 Ha\u2019arba\u2019a Street", "city": "Tel Aviv", "zip": "6473921", "country": "Israel", "phone": "972 3 541 3131", "fax": "972 3 541 3144", "website": "https://www.redhillbio.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "industryDisp": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Dror  Ben-Asher", "age": 56, "title": "Co-Founder, CEO & Director", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 734594, "fmt": "734.59k", "longFmt": "734,594"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Gilead  Raday MPhil, MSc", "age": 47, "title": "Chief Operating Officer", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": {"raw": 445385, "fmt": "445.38k", "longFmt": "445,385"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Adi  Frish", "age": 52, "title": "Chief Corp. & Bus. Devel. Officer", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": {"raw": 419502, "fmt": "419.5k", "longFmt": "419,502"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Rick D. Scruggs", "age": 62, "title": "Chief Commercial Officer, Pres of RedHill Biopharma Inc. & Director", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": {"raw": 607046, "fmt": "607.05k", "longFmt": "607,046"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Micha  Ben-Chorin", "age": 53, "title": "Advisor", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 454205, "fmt": "454.2k", "longFmt": "454,205"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Razi  Ingber", "age": 38, "title": "Chief Financial Officer", "yearBorn": 1984, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Mark L. Levitt M.D., Ph.D.", "title": "Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Alexandra  Okmian", "title": "Sr. Bus. Devel. & Investor Relations Mang.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Kristin  Comer", "title": "VP, Gen. Counsel & Chief Compliance Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Rob  Jackson", "title": "Sr. VP of Sales & Marketing", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}